Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
PIK3CA E545K
Cancer:
HER2 Positive Breast Cancer
Drug:
Kadcyla (ado-trastuzumab emtansine)
(
Microtubule inhibitor
,
HER2-targeted antibody-drug conjugate
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Clin Cancer Res
Title:
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Excerpt:
At concentrations ≥0.01 μg/mL, sensitivity to T-DM1 was observed across all cell lines with various activating PIK3CA mutations (Fig. 3).
DOI:
10.1158/1078-0432.CCR-15-2499
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login